Cancer Stem Cell News Volume 9.45 | Dec 2 2020

    0
    6







    2020-12-02 | CSCN 9.45


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.45 – 2 December, 2020
    TOP STORY

    A
    Stem Cell Reporter Based Platform to Identify and Target Drug Resistant Stem Cells in Myeloid Leukemia

    Investigators showed that a knock-in reporter mouse for the stem cell gene Musashi 2 allowed identification of leukemia stem cells in aggressive myeloid malignancies, and provided a strategy for defining their core dependencies.
    [Nature Communications]

    Full Article

    Survey Report: Where Is Pluripotent Stem Cell Research Now?
    PUBLICATIONSRanked by the impact factor of the journal

    Alpha
    1-Antichymotrypsin Contributes to Stem Cell Characteristics and Enhances Tumorigenicity of Glioblastoma

    Researchers utilized patient-derived cerebrospinal fluid and primary cultures of glioblastoma brain tumor initiating cells. They determined the impact of SERPINA3 expression in glioma patients using TCGA database. SERPINA3 expression changes were evaluated at both the mRNA and protein levels.
    [Neuro-Oncology]

    Abstract

    ZFHX3
    Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription

    The authors found that ZFHX3 promoted the proliferation and tumor growth of breast cancer cells in culture and nude mice; and higher expression of ZFHX3 in human breast cancer specimens was associated with poorer prognosis.
    [Cancers]

    Full Article

    Silencing
    hTERT Attenuates Cancer Stem Cell-Like Characteristics and Radioresistance in the Radioresistant Nasopharyngeal Carcinoma Cell Line CNE-2R

    Silencing hTERT suppressed CNE-2R cell proliferation and increased the cell apoptosis rate and radiosensitivity in vitro. Moreover, it could also inhibit the growth of xenografts and increase the apoptosis index and radiosensitivity in vivo.
    [Aging]

    Full Article

    Nitric
    Oxide-Targeted Therapy Inhibits Stemness and Increases the Efficacy of Tamoxifen in Estrogen Receptor-Positive Breast Cancer Cells

    Investigators explored whether targeting nitric oxide in estrogen positive breast cancer cells impacts cancer stem cell subpopulation and sensitivity to hormonal therapy with tamoxifen.
    [Laboratory Investigation]

    Abstract

    Histone
    Demethylase JMJD2D Promotes the Self-Renewal of Liver Cancer Stem-Like Cells by Enhancing EpCAM and Sox9 Expression

    Researchers showed that histone lysine demethylase 4D (JMJD2D) expression was increased in liver cancer stem-like cells (LCSCs); downregulation of JMJD2D inhibited the self-renewal of LCSCs in vitro and in vivo and inhibited the lung metastasis of LCSCs by reducing the survival and the early lung seeding of circulating LCSCs.
    [Journal of Biological Chemistry]

    AbstractFull Article

    Comprehensive
    Analysis of Inhibitory Checkpoint Ligand Expression by Glioblastoma Cells

    Scientists showed that glioblastoma cells express a large repertoire of inhibitory checkpoint ligands known to control effector T cell responses. Flow cytometry analysis revealed that glioblastoma cells with an enhanced stem cell‐like phenotype express several investigated ligands at significant levels on their cell surface.
    [Immunology and Cell Biology]

    Abstract

    Hepatocellular
    Carcinoma: Intratumoral EpCAM-Positive Cancer Stem Cell Heterogeneity Identifies High-Risk Tumor Subtype

    The authors investigated the spatial heterogeneity of cancer stem cell-features with the aim of identifying the unique hepatocellular carcinoma patient subgroups amenable to adjuvant treatment.
    [BMC Cancer]

    Full Article

    In Silico and In Vitro
    Studies on the Anti-Cancer Activity of Andrographolide Targeting Survivin in Human Breast Cancer Stem Cells

    Human CD24/CD44+ breast cancer stem cells (BCSCs) were treated with andrographolide in vitro for 24 hours. The cytotoxic effect of andrographolide on BCSCs was compared to that on human mesenchymal stem cells.
    [PLoS One]

    Full Article
    How can evaluating the immuno-oncology potential of compounds in vitro predict clinical outcomes? Watch this webinar by Dr. Alison O'Mahony, Eurofins DiscoverX
    REVIEWS

    Medicinal
    Chemistry Targeting Mitochondria: From New Vehicles and Pharmacophore Groups to Old Drugs with Mitochondrial Activity

    Mitochondrial inhibition may be a viable strategy for eradicating cancer stem cells. Medicinal chemistry research over the last decade has synthesized and characterized “vehicles” capable of transporting novel or existing pharmacophores to mitochondrial tumor cells, based on mechanisms that exploit the physicochemical properties of the vehicles and the inherent properties of the mitochondria.
    [International Journal of Molecular Sciences]

    Full ArticleGraphical Abstract

    EMT,
    Cancer Stem Cells and Autophagy; the Three Main Axes of Metastasis

    The authors investigate and elucidate the relationship between the effective signaling pathways in CSCs, autophage, and epithelial-mesenchymal transition, which could play an effective role in determining appropriate therapeutic goals.
    [Biomedicine & Pharmacotherapy]

    AbstractGraphical Abstract

    INDUSTRY AND POLICY NEWS

    Imago BioSciences Expands Phase II Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong

    Imago BioSciences, Inc. announced the expansion of its global Phase IIb clinical study evaluating bomedemstat for the treatment of advanced myelofibrosis into Hong Kong, where the first patient has now been enrolled and dosed. Myelofibrosis is a rare bone marrow cancer that interferes with the production of blood cells.
    [Imago BioSciences, Inc.]

    Press Release

    Forma
    Therapeutics Announces Positive Top-Line Olutasidenib Data from a Planned Interim Analysis of a Registrational Phase II Clinical Trial in Acute Myeloid Leukemia

    Forma Therapeutics Holdings, Inc. announced positive top-line data from a planned interim analysis of a registrational Phase II clinical trial of olutasidenib, Forma’s selective inhibitor for hematological malignancy cancers with mutations in isocitrate dehydrogenase 1.
    [Forma Therapeutics Holdings, Inc. (BusinessWire, Inc.)]

    Press Release
    FEATURED EVENT

    Gordon Research Conferences: Stem Cells and Cancer

    May 16 – May 21, 2021
    Lucca, Italy


    > See All Events

    JOB OPPORTUNITIES

    Faculty Position – Skin Cancer

    Columbia University Medical Center – New York, New York, United States

    Senior
    Investigator – Replication Stress and Chromatin Alterations

    NIH National Cancer Institute – Bethesda, Maryland, United States

    Postdoctoral
    Research Assistant – Glioblastoma

    Queen Mary University of London – London, England, United Kingdom

    Dean and Faculty Positions – Brain Cancer Biology

    Peking University Shenzhen Graduate School – Shenzhen, China

    Postdoctoral Fellow – Melanoma Research

    Universitätsklinikum Carl Gustav Carus Dresden – Dresden, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter